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Abstract 
Background: Acute myeloid leukemia (AML) carrying nucleophosmin 1 (NPM1) mutations (NPMc+) is regarded 
as a separate entity of myeloid neoplasms due to its distinct biological and clinical features. However, NPMc+ alone 
displays low leukemogenic activity and cooperating events appear crucial for AML to develop. Dysregulation of 
homeobox genes, such as HOXA9 and MEIS1, is a common transcriptional signature of NPMc+ AML. Furthermore, the 
pathogenic role for NPMc+ in AML remains incompletely understood.
Aim: To elucidate if NPMc+ collaborates with Meis1 or Hoxa9 in the evolvement of AML.
Methods: Murine bone marrow cells were genetically engineered to express mutated NPM1 variant A in combina-
tion with overexpression of Meis1 or Hoxa9. The capacity of the transduced cells to transform in vitro and to cause 
leukemia in vivo was then assessed.
Findings and conclusion: There was no synergy between NPMc+ and Meis1 or Hoxa9 in causing leukemogenic 
transformation of murine bone marrow cells, or in inducing AML in a transplantation model. Hence, overexpression of 
Meis1 or Hoxa9 in combination with NPMc+ expression was not sufficient to generate an NPMc+ AML mouse model.
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Background
Nucleophosmin (NPM1) is found mutated in about 30 % 
of acute myeloid leukemia (AML) cases, making it one of 
the most commonly mutated genes in AML [1, 2]. Wild-
type NPM1 has been ascribed many biological func-
tions, including a role in the biogenesis of ribosomes, 
genomic stability and transport of small basic proteins to 
the nucleus [3]. The NPM1 mutations occurring in AML 
disrupts the nucleolar localization signal of NPM1 and 
generates a nuclear export signal in its place, resulting 
in aberrant cytoplasmic localization of mutated NPM1 
(NPMc+) [4]. Since 2008, the World Health Organization 
regards AML with mutated NPM1 as a provisional AML 
entity due to its unique characteristics [5]. Despite the 
recognition of mutated NPM1 as a founder genetic lesion 
[6] and a putative target for novel therapy [7], the mecha-
nism by which NPMc+ contributes to leukemogenesis 
has only partly been explored. Animal models of NPMc+ 
AML, aiming at understanding the NPM1-driven leuke-
mogenesis, have thus far revealed that NPMc+ alone dis-
plays low leukemogenic activity [8, 9] and that additional 
cooperative mutations, such as FLT3-ITD [10] or N-ras 
mutations [9] are required for AML to develop.
Gene expression data from both NPM1-mutated adult 
and pediatric AML cases have identified an association 
between NPMc+ and dysregulated expression of home-
obox (HOX) and TALE genes, including Hoxa9 and 
Meis1, which are known to be involved in hematopoi-
etic development [11–14]. In accordance, Ogawara et al. 
reported that NPMc+ expression in c-Kit+ bone marrow 
(BM) cells results in increased expression of Hoxa9 [15]. 
Hoxa9 and Meis1 are primarily expressed at the level of 
hematopoietic stem and progenitor cells during normal 
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hematopoiesis [16] and have been shown to cooperate in 
causing AML in transplantation mouse models [17, 18]. 
The presumed NPMc+-induced Hoxa9 expression incited 
us to investigate a potential synergy between NPMc+ and 
Meis1 in causing AML. To test this hypothesis, and in 
an attempt to develop a transplantation model reliant on 
NPMc+ expression for in vivo onset of AML, C57BL/6 J 
bone marrow cells were transduced to express NPMc+ 
in combination with overexpression of either Meis1 
or Hoxa9. However, we could not find any evidence for 
cooperation between NPMc+ expression and Meis1 or 
Hoxa9 overexpression in leukemogenic transforma-
tion. Thus, our data show that overexpression of Meis1 
or Hoxa9 is not sufficient to cause AML in combination 




The following vectors have been previously described: 
MSCV-IRES-GFP (GFP virus) [19], MSCV-IRES-YFP 
(YFP virus) [20], MSCV-IRES-neo (neo virus) [21], 
MSCV-HA-Meis1a-IRES-YFP (Meis1 virus) [19], and 
MSCV-Hoxa9-IRES-neo (Hoxa9 virus) [21]. The sequence 
for the most common NPM1 mutation, mutation A, was 
purchased from Integrated DNA Technologies (Coralville, 
IA, USA), inserted into the MSCV-IRES-GFP vector and 
used to transiently transfect Phoenix Eco cells (ATCC, 
LGC Standards GmbH, Wesel, Germany). Virus-contain-
ing medium from Phoenix Eco was utilized to transduce 
GP  +  E86 cells (ATCC, LGC Standards GmbH, Wesel, 
Germany) and generate a stable NPMc+ viral producer.
Transduction of C57BL/6 J bone marrow cells
All mice experiments were approved by the Animal Eth-
ics Research Committee in Gothenburg. C57BL/6 J mice 
were obtained from Charles River Laboratories (Sulzfeld, 
Germany). Transduction of C57BL/6 J BM with viral vec-
tors was performed as previously described [22]. In brief, 
murine BM cells harvested from C57BL/6 J mice 4 days 
after 150  µg/g 5-fluorouracil (5-FU, Accord Healthcare 
AB, Solna, Sweden) treatment were transduced with 
NPMc+ and neo or YFP viruses (NPMc+ cells), Meis1 and 
GFP viruses (Meis1 cells), Hoxa9 and GFP viruses (Hoxa9 
cells), Meis1 and NPMc+ viruses (Meis1-NPMc+ cells) or 
Hoxa9 and NPMc+ viruses (Hoxa9-NPMc+ cells) and 
cultured in Dulbecco modified Eagle medium (DMEM 
with high glucose, D6429, Sigma-Aldrich Sweden AB, 
Stockholm, Sweden) supplemented with 15 % fetal bovine 
serum (6250, StemCell Technologies Inc., Vancouver, 
Canada), 2  mM  l-glutamine (G7513-100  ml, Sigma-
Aldrich Sweden AB, Stockholm, Sweden), 1 % Penicillin 
and streptomycin (P4333-100 ml, Sigma-Aldrich Sweden 
AB, Stockholm, Sweden), 10 ng/ml human interleukin-6 
(2506, StemCell Technologies SARL, Grenoble, France), 
6 ng/ml murine interleukin-3 (2733, StemCell Technolo-
gies SARL, Grenoble, France), and 50 ng/ml murine stem 
cell factor (2931 StemCell Technologies SARL, Grenoble, 
France) (complete medium). Transduction was achieved 
by co-culturing 5-FU treated murine BM cells with irra-
diated (2  ×  25 Gray) GP  +  E86 viral cells in complete 
medium supplemented with 5  µg/ml protamine sulfate 
(P-4020, Sigma-Aldrich Sweden AB, Stockholm, Swe-
den). Two days later, gentle flushing of the wells separated 
non-adherent BM cells from adherent viral cells. BM cells 
were pelleted, resuspended in fresh complete culture 
medium and expanded for 5  days. Selection of trans-
duced cells was achieved by addition of 0.3 mg/ml G418 
disulfate salt solution (G8168-10 ml, Sigma-Aldrich Swe-
den AB, Stockholm, Sweden) to the culture medium fol-
lowed by sorting of GFP+/YFP+ cells on a three-laser BD 
FACSAria (405, 488 and 633 nm from BD Biosciences).
BM transplantation of C57BL/6 J mice
Transduced BM cells were injected into the tail vein of 
lethally irradiated (800 cGray) C57BL/6 J mice 1 day after 
FACS selection of transduced cells. Transplants consisted 
of 100 000 to 200 000  NPMc+, Meis1, Hoxa9, Meis1-
NPMc+ or Hoxa9-NPMc+ cells and two million life-spar-
ing naïve BM cells. Mice were monitored daily during 
the initial 2 weeks for signs of morbidity. Analyzing the 
percentage of GFP+/YFP+ cells in peripheral blood, with 
a four-laser BDLSRFortessa (405, 488, 532 and 640  nm 
from BD Biosciences), allowed monitoring of engraft-
ment and disease progression in real-time.
Quantitative real‑time PCR
BM cells were stored in RNAprotect Cell Reagent (76526, 
Qiagen AB, Sollentuna, Sweden) until total RNA was 
extracted using the RNeasy Plus Mini kit (74136, Qia-
gen AB, Sollentuna, Sweden) and cDNA synthesized by 
SuperScript III First-Strand Synthesis SuperMix for qRT-
PCR (11752, Invitrogen, Life Technologies Europe BV, 
Stockholm, Sweden) all according to the manufacturer’s 
instructions. Gene expression was analyzed by TaqMan 
Gene Expression Assays; hNPM1, Hs02339479_g1; 
hNPM1mutA, Hs00000953_mu; mHoxa9, Mm00439364_
m1; hMeis1, Hs00180020_m1; and as reference gene, 
mHPRT1, Mm01545399_m1 (Applied Biosystems, Life 
Technologies Europe BV, Stockholm, Sweden) according to 
the manufacturer’s instructions on a ABI PRISM®7900HT 
instrument (Applied Biosystems, Life Technologies Europe 
BV, Stockholm, Sweden). Gene expression results are pre-
sented as 2^-[Ct(target)-Ct (HPRT1)].
Page 3 of 7Wiktorin et al. Exp Hematol Oncol  (2016) 5:25 
Sequencing
Genomic DNA was isolated from the BM cells 21  days 
post transduction with the DNeasy Blood & Tissue kit 
(69504, Qiagen AB, Sollentuna, Sweden). The sequence 
over the NPM1 mutation site was analyzed by Sanger 
sequencing utilizing the BigDye Terminator v3.1 Cycle 
Sequencing kit (4337455, Applied Biosystems, Ther-
moFisher Scientific, Hagersten, Sweden) on a 3130xl 
Genetic Analyzer.
Methylcellulose colony forming assay
Colony forming unit (CFU) assay was used to evaluate 
the proliferative capacity of cells after transduction with 
above mentioned genes. 100 to 5000 cells were seeded in 
methylcellulose medium (Methocult M3434, StemCell 
Technologies SARL, Grenoble, France). After 7 days, the 
number of colonies was counted and the following day 
cells were replated.
May‑Grünwald‑Giemsa staining
Using a Shandon CytoSpin 2 (Axel Johnson Instrument 
AB, Stockholm, Sweden), transduced BM cells were 
sprayed onto glass slides and allowed to air-dry. Slides 
were May-Grünwald-Giemsa stained and images taken 
on a Nikon Eclipse 90i microscope.
Statistics
For statistical analyses, Student´s unpaired t test was 
performed. All statistical analyses were calculated using 
GraphPad Prism Version 6.0.
Results
To clarify whether NPMc+ and Meis1 or Hoxa9 coop-
erate in induction of AML, 5-FU-treated BM cells from 
C57BL/6  J mice were transduced with aforementioned 
genes as outlined in Fig. 1a. Successfully transduced cells 
were FACS-sorted based on GFP and/or YFP expression 
Fig. 1 Transduction of murine bone marrow cells with NPMc+, Meis1 and Hoxa9. a The table shows the combination of genes murine bone mar-
row cells were transduced with. b–d RNA was extracted from transduced cells using the RNeasy Plus Mini kit and analyzed by qPCR for expression 
of human NPM1 (b), human MEIS1 (c) and murine Hoxa9 (d). For all qPCR analysis n = 3. The bars indicate mean ± SD. Statistical calculations were 
performed using Student´s unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001
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and sorted cells were utilized in the further experi-
ments. Quantitative  PCR  (qPCR) analysis confirmed 
increased mRNA expression levels of NPMc+, Meis1 and 
Hoxa9 in all transduced cells (Fig.  1b–d). The presence 
of the correct sequence of mutated NPM1 in the trans-
duced NPMc+ BM cells was verified by sequencing. No 
enhancement of Hoxa9 expression was observed in the 
NPMc+ liquid cultures (Fig. 1d).
Next, the transfected cells were analyzed by CFU 
assays to investigate a potential synergy between NPMc+ 
and Meis1 or Hoxa9 in leukemogenic transformation. 
Cells were cultured in methylcellulose medium for 
7 days before enumeration of colonies. Cells transduced 
with NPMc+, Meis1 or Hoxa9 all showed enhanced 
serial colony-forming activity, compared with control 
cells transduced only with the selection markers, neo, 
GFP or YFP, where virtually no colonies were formed 
after the first replating (Fig.  2a). The colony forming 
capacity was highest in cells overexpressing Hoxa9 but 
no significant differences were observed in colony for-
mation of single transduced cells and cells transduced to 
express both NPMc+ and Meis1 or NPMc+ and Hoxa9 
(Fig. 2a). Similarly, it was noticed that only cells overex-
pressing Hoxa9 (in the presence or absence of NPMc+) 
became immortalized and survived long-term in  vitro 
cultures.
In support of the necessity of increased Hoxa9 levels for 
improved proliferative capacity, May-Grünewald-Giemsa 
staining of cells revealed that Hoxa9 expression was 
required for cells to maintain a blast-like cell-morphology 
(Fig. 2d and f ). In the absence of increased Hoxa9 expres-
sion levels, cells differentiated and mainly displayed the 
morphology of monocytes, macrophages and neutrophils 
(Fig. 2b, c and e).
Colony-forming capability in  vitro often mirrors the 
potential of cells to engraft in mice [23]. In accordance, 
transplantation with NPMc+, Meis1 or Meis1-NPMc+ 
cells (in combination with life-sparing BM cells) to 
lethally irradiated C57BL/6  J mice did not lead to long-
term engraftment, as the percentage of transfected cells 
in the blood of the mice was consistently below 1.5  % 
(Fig.  2g). In contrast, transplantation with Hoxa9 and 
Hoxa9-NPMc+ cells led to long-term engraftment of leu-
kemic cells, albeit at a low level (Fig. 2g). Three out of five 
mice transplanted with Hoxa9 cells developed late onset 
leukemia, with the first mice progressing into leukemia 
displaying disease symptoms, as determined by increased 
white blood cell counts along with an increased fre-
quency of GFP+/YFP+ leukemic cells in blood, approxi-
mately 16 weeks after transplantation (Fig. 2g). None of 
the mice transplanted with Hoxa9-NPMc+ cells showed 
signs of disease progression within the 20-week observa-
tion period (Fig. 2g).
Discussion
Our in vitro and in vivo results consistently demonstrate 
a lack of synergy between NPMc+ and Meis1 or Hoxa9 
in terms of transforming murine bone marrow cells and 
causing AML in an experimental transplantation model. 
Although NPMc+ has been associated with enhanced 
Hoxa9 expression in AML patients [11] and in trans-
duced murine BM cells [15], we did not observe enhanced 
expression in our NPMc+ liquid cultures (Fig.  1d). The 
reason for absent Hoxa9 induction and for the low leu-
kemogenic capacity of the NPMc+ cells utilized in our 
study might be that normal levels of wild-type NPM1 
was expressed by the transduced BM cells. Hence, NPM1 
mutations in patients might cause disease both by caus-
ing a reduced expression of wild-type NPM1 (expression 
from only one allele), and by the oncogenic activity of 
NPMc+. NPM1 mutations are always heterozygous and a 
complete knock out of the protein results in embryonic 
lethality in mice [24]. However, mice genetically engi-
neered to express only one wild-type NPM1 allele display 
a higher susceptibility to hematological malignancies, 
including myeloid leukemia, indicating that loss of NPM1 
function is a mechanism of pathogenicity [25].
Since NPM1 mutations in AML always result in cyto-
plasmic localization of the protein, it is conceivable that 
NPMc+ plays a crucial role in pathogenicity. NPMc+ has 
been ascribed oncogenic functions [26–28] and trans-
genic mice expressing NPMc+ within the myeloid com-
partment develop a myeloproliferative disease, albeit no 
AML [8]. To mimic the situation in human AML, con-
ditional knock-in models, referred to as Npm1cA/+ mice, 
have been developed where NPMc+ is expressed in 
mice that display reduced expression-levels of wild-type 
NPM1. In this setting, one-third of the Npm1cA/+ mice 
developed late onset AML, indicating a more aggressive 
course of disease [9].
Furthermore, when NPMc+ was introduced to BM cells 
from transgenic NPM1+/− mice, the increase in Hoxa9 
expression was much greater than when NPMc+ was 
introduced to wild type BM cells [15]. However, in this 
previous study, even NPMc+ expressing NPM+/− bone 
marrow cells failed to cause AML when transplanted into 
irradiated mice, highlighting the importance of coopera-
tive genes [15]. Thus, even in conditions of reduced wild 
type NPM1 expression, the selection of genes to coop-
erate with NPMc+ in triggering AML is crucial. We and 
others have previously shown that Hoxa9 and Meis1 act 
in synergy to cause leukemia in transplantation models 
[17, 29]. Since NPMc+ should trigger an enhanced Hoxa9 
expression on a NPM1+/− background [15], it is conceiv-
able that NPMc+ should cooperates with Meis1 in causing 
AML if NPM1+/− bone marrow cells would be utilized, 
which merits further studies. Cells overexpressing Hoxa9 
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Fig. 2 No synergy in transforming capacity of NPMc+ and Meis1 or Hoxa9. a Percentage of single and double transduced cells forming colonies on 
methocult plates after serial replatings: Control (empty GFP+/YFP+ vector) (n = 4 at replate 1 and n = 2 at replate 2), NPMc+ (n = 7 at replate 1 
and 2 and n = 5 at replate 3), Meis1 (n = 3), Hoxa9 (n = 10 at replate 1 and 2, n = 7 at replate 3), Meis1-NPMc+ (n = 3), and Hoxa9-NPMc+ (n = 4 at 
replate 1 and 2 and n = 2 at replate 3). b–f Representative images from May-Grünewald-Giemsa staining showing NPMc+ cells (b), Meis1 cells  
(c), Hoxa9 cells (d), Meis1-NPMc+ cells (e) and Hoxa9-NPMc+ cells (f). g The percentage of NPMc+ , Meis1, Hoxa9, Meis1-NPMc+ and Hoxa9-
NPMc+ cells (reflected by GFP+/YFP+ expression) in peripheral blood was monitored by flow cytometry during 21 weeks. NPMc+ (n = 8), Meis1 
(n = 5), Hoxa9 cells (n = 5), Meis1-NPMc+ cells (n = 5), and Hoxa9-NPMc+ (n = 10). Error bars show ± standard error of the mean (SEM)
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showed an increased colony forming and disease causing 
capacity compared with cells not overexpressing Hoxa9. 
However, our results indicate, if anything, a reduced dis-
ease causing potential of Hoxa9-NPMc+ cells compared 
with Hoxa9 overexpressing cells alone, which do not 
incite additional studies of synergy between NPMc+ and 
Hoxa9.
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